TY - JOUR
T1 - Associations Between Aldosterone-Renin-Ratio and Bone Parameters Derived from Peripheral Quantitative Computed Tomography and Impact Microindentation in Men
AU - Holloway-Kew, Kara L.
AU - Anderson, Kara B.
AU - Rufus-Membere, Pamela
AU - Tembo, Monica C.
AU - Sui, Sophia X.
AU - Hyde, Natalie K.
AU - Kotowicz, Mark A.
AU - Gwini, Stella M.
AU - Yang, Jun
AU - Diez-Perez, Adolfo
AU - Henneberg, Maciej
AU - Liao, Wan Hui
AU - Pasco, Julie A.
N1 - Funding Information:
Open Access funding enabled and organized by CAUL and its Member Institutions. Amgen Inc., National Health and Medical Research Council, 251638, Julie A Pasco, 299831, Julie A Pasco, 628582, Julie A Pasco, Alfred Deakin Postdoctoral Research Fellowship, Australian Government Research Training Program Scholarship, Deakin University Postgraduate Industry Research Scholarship, Deakin Postgraduate Scholarship, Dean’s Research Postdoctoral Fellowship (Deakin University), Institute for Mental and Physical Health and Clinical Translation Seed Funding Grant, Victorian Government Operational Infrastructure Scheme.
Funding Information:
This study was funded by grant support of Amgen Inc. and the National Health and Medical Research Council (NHMRC; grants 251638, 299831, 628582), but they played no role in the collection or interpretation of data. KLH-K is supported by an Alfred Deakin Postdoctoral Research Fellowship; KBA by an Australian Government Research Training Program Scholarship; PR-M by a Deakin University Postgraduate Industry Research Scholarship; MT by a Deakin Postgraduate Scholarship; SXS and NKH by Dean’s Research Postdoctoral Fellowships (Deakin University). SMG received an Institute for Mental and Physical Health and Clinical Translation Seed Funding Grant which supported the measurement of aldosterone and renin. AD-P owns shares of Active Life Scientific, Inc., the manufacturer of the reference point indentation device. MH supports his research activities from his own savings. MAK, W-HL, MH and JAP declare they have no conflict of interest. The Hudson Institute is supported by the Victorian Government’s Operational Infrastructure Scheme. The authors thank Professor Graham Giles of the Cancer Epidemiology Centre of The Cancer Council Victoria, for permission to use the Dietary Questionnaire for Epidemiological Studies (Version 2), Melbourne: The Cancer Council Victoria 1996. The authors also thank the Victorian Cancer Register for data linkage.
Funding Information:
This study was funded by grant support of Amgen Inc. and the National Health and Medical Research Council (NHMRC; grants 251638, 299831, 628582), but they played no role in the collection or interpretation of data. KLH-K is supported by an Alfred Deakin Postdoctoral Research Fellowship; KBA by an Australian Government Research Training Program Scholarship; PR-M by a Deakin University Postgraduate Industry Research Scholarship; MT by a Deakin Postgraduate Scholarship; SXS and NKH by Dean’s Research Postdoctoral Fellowships (Deakin University). SMG received an Institute for Mental and Physical Health and Clinical Translation Seed Funding Grant which supported the measurement of aldosterone and renin. AD-P owns shares of Active Life Scientific, Inc., the manufacturer of the reference point indentation device. MH supports his research activities from his own savings. MAK, W-HL, MH and JAP declare they have no conflict of interest. The Hudson Institute is supported by the Victorian Government’s Operational Infrastructure Scheme. The authors thank Professor Graham Giles of the Cancer Epidemiology Centre of The Cancer Council Victoria, for permission to use the Dietary Questionnaire for Epidemiological Studies (Version 2), Melbourne: The Cancer Council Victoria 1996. The authors also thank the Victorian Cancer Register for data linkage.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/11
Y1 - 2023/11
N2 - Components of the renin–angiotensin–aldosterone system (RAAS) are present on bone cells. One measure of RAAS activity, the aldosterone-renin-ratio (ARR), is used to screen for primary aldosteronism. Associations between ARR and bone mineral density are conflicting. This study investigated associations between ARR and peripheral quantitative computed tomography (pQCT) and impact microindentation (IMI). Male participants (n = 431) were from the Geelong Osteoporosis Study. “Likely” primary aldosteronism was defined as ARR ≥ 70 pmol/mIU. Another group, “possible” primary aldosteronism, was defined as either ARR ≥ 70 pmol/mIU or taking a medication that affects the RAAS, but not a beta blocker, and renin < 15 mU/L. Using pQCT, images at 4% and 66% of radial (n = 365) and tibial (n = 356) length were obtained. Using IMI measurements, bone material strength index (BMSi; n = 332) was determined. Associations between ARR or likely/possible primary aldosteronism and IMI or pQCT-derived bone parameters were tested using median regression. ARR and aldosterone values were not associated with any of the pQCT-derived bone variables in either unadjusted or adjusted analyses. Men with likely primary aldosteronism (n = 16), had lower adjusted total bone area (radial 66% site, − 12.5%). No associations were observed for men with possible primary aldosteronism (unadjusted or adjusted). No associations with BMSi were observed (p > 0.05). There were no associations between ARR or aldosterone and pQCT-derived bone parameters. Men with likely primary aldosteronism had lower bone area, suggesting clinically high levels of ARR may have a negative impact on bone health.
AB - Components of the renin–angiotensin–aldosterone system (RAAS) are present on bone cells. One measure of RAAS activity, the aldosterone-renin-ratio (ARR), is used to screen for primary aldosteronism. Associations between ARR and bone mineral density are conflicting. This study investigated associations between ARR and peripheral quantitative computed tomography (pQCT) and impact microindentation (IMI). Male participants (n = 431) were from the Geelong Osteoporosis Study. “Likely” primary aldosteronism was defined as ARR ≥ 70 pmol/mIU. Another group, “possible” primary aldosteronism, was defined as either ARR ≥ 70 pmol/mIU or taking a medication that affects the RAAS, but not a beta blocker, and renin < 15 mU/L. Using pQCT, images at 4% and 66% of radial (n = 365) and tibial (n = 356) length were obtained. Using IMI measurements, bone material strength index (BMSi; n = 332) was determined. Associations between ARR or likely/possible primary aldosteronism and IMI or pQCT-derived bone parameters were tested using median regression. ARR and aldosterone values were not associated with any of the pQCT-derived bone variables in either unadjusted or adjusted analyses. Men with likely primary aldosteronism (n = 16), had lower adjusted total bone area (radial 66% site, − 12.5%). No associations were observed for men with possible primary aldosteronism (unadjusted or adjusted). No associations with BMSi were observed (p > 0.05). There were no associations between ARR or aldosterone and pQCT-derived bone parameters. Men with likely primary aldosteronism had lower bone area, suggesting clinically high levels of ARR may have a negative impact on bone health.
KW - Aldosterone-renin-ratio
KW - Bone material strength index
KW - Impact microindentation
KW - Males
KW - Peripheral quantitative computed tomography
KW - Primary aldosteronism
UR - https://www.scopus.com/pages/publications/85170230157
U2 - 10.1007/s00223-023-01131-x
DO - 10.1007/s00223-023-01131-x
M3 - Article
C2 - 37690031
AN - SCOPUS:85170230157
SN - 0171-967X
VL - 113
SP - 496
EP - 510
JO - Calcified Tissue International
JF - Calcified Tissue International
IS - 5
ER -